vs
INFINITY NATURAL RESOURCES, INC.（INR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是INFINITY NATURAL RESOURCES, INC.的1.8倍（$207.3M vs $115.5M），INFINITY NATURAL RESOURCES, INC.净利率更高（17.3% vs -62.0%，领先79.4%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
INR vs RARE — 直观对比
营收规模更大
RARE
是对方的1.8倍
$115.5M
净利率更高
INR
高出79.4%
-62.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $115.5M | $207.3M |
| 净利润 | $20.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 47.0% | -54.7% |
| 净利率 | 17.3% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $1.33 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INRRARE
| Q4 25 | $115.5M | $207.3M | ||
| Q3 25 | $78.3M | $159.9M | ||
| Q2 25 | $72.5M | $166.5M | ||
| Q1 25 | $84.2M | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | — | $139.5M | ||
| Q2 24 | — | $147.0M | ||
| Q1 24 | — | $108.8M |
净利润INRRARE
| Q4 25 | $20.0M | $-128.6M | ||
| Q3 25 | $10.4M | $-180.4M | ||
| Q2 25 | $18.0M | $-115.0M | ||
| Q1 25 | $-34.6M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | — | $-133.5M | ||
| Q2 24 | — | $-131.6M | ||
| Q1 24 | — | $-170.7M |
营业利润率INRRARE
| Q4 25 | 47.0% | -54.7% | ||
| Q3 25 | 30.5% | -106.9% | ||
| Q2 25 | 29.9% | -64.8% | ||
| Q1 25 | -104.5% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率INRRARE
| Q4 25 | 17.3% | -62.0% | ||
| Q3 25 | 13.3% | -112.8% | ||
| Q2 25 | 24.8% | -69.0% | ||
| Q1 25 | -41.1% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | — | -95.7% | ||
| Q2 24 | — | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益（稀释后）INRRARE
| Q4 25 | $1.33 | $-1.28 | ||
| Q3 25 | $0.65 | $-1.81 | ||
| Q2 25 | $1.18 | $-1.17 | ||
| Q1 25 | $-2.27 | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.8M | $421.0M |
| 总债务越低越好 | $55.0K | — |
| 股东权益账面价值 | $307.1M | $-80.0M |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资INRRARE
| Q4 25 | $2.8M | $421.0M | ||
| Q3 25 | $4.6M | $202.5M | ||
| Q2 25 | $6.3M | $176.3M | ||
| Q1 25 | $4.9M | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
总债务INRRARE
| Q4 25 | $55.0K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $123.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益INRRARE
| Q4 25 | $307.1M | $-80.0M | ||
| Q3 25 | $288.6M | $9.2M | ||
| Q2 25 | $10.1M | $151.3M | ||
| Q1 25 | $-52.2M | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | — | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
总资产INRRARE
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $953.9M | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.3B |
负债/权益比INRRARE
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.75× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流INRRARE
| Q4 25 | $75.1M | $-99.8M | ||
| Q3 25 | $42.1M | $-91.4M | ||
| Q2 25 | $70.4M | $-108.3M | ||
| Q1 25 | $74.2M | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | — | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | — | $-190.7M |
自由现金流INRRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率INRRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度INRRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率INRRARE
| Q4 25 | 3.75× | — | ||
| Q3 25 | 4.04× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INR
| Oil Reserves | $54.0M | 47% |
| Natural Gas Reserves | $46.8M | 41% |
| Natural Gas Liquids Reserves | $14.7M | 13% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
